Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006

Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006

0:00
16 November 2006

Judith Hochman Timothy Gardner Girish Mood Marc Cohen Late Opening of Total Occlusion: No Benefit from PCI for Patients with STEMI REFERENCE: LBCT II News Conference November 14th 2006 JUDITH HOCHMAN,

Judith Hochman

Judith Hochman

Timothy Gardner

Timothy Gardner

Girish Mood

Girish Mood

Marc Cohen

Marc Cohen

Late Opening of Total Occlusion: No Benefit from PCI for Patients with STEMI

REFERENCE: LBCT II News Conference November 14th 2006JUDITH HOCHMAN, New York University School of MedicineCOMMENT: TIMOTHY GARDNER, Christiana Care, DelawareOpening a patient’s occluded artery between 3-28 days after a myocardial infarction does not improve outcome.Judith Hochmanpresented surprising data from the Occluded Artery Trial (OAT) that showed the addition of PCI to optimal medical treatment was no better than medical therapy alone. Sarah Maxwell heard more from her at the American Heart Association meeting in Chicago.

Aggressive Statins: Big Benefit in Elective Angioplasty

REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract 3074: Poster C239 TuesdayGIRISH MOOD, Cleveland Clinic, OhioAggressive statin therapy is recommended for patients receiving elective percutaneous intervention according to researchers at the Cleveland Clinic. At the AHA Sessions in ChicagoGirish Moodtold Peter Goodwin about the meta analysis they’ve done which endorses intense use of statins.

Bleeding Risk Score in Patients Having Elective Angioplasty

American Heart Association Scientific Sessions 2006 November 12-15th Chicago, Illinois. Abstract: 3073: Poster C 238, TuesdayMARC COHEN, Mt Sinai School of Medicine, Newark NJA simple score to predict bleeding risk among patients having elective angioplasty has come out of the international STEEPLE Trial looking at 3500 patients.Marc Cohentold Peter Goodwin at the AHA Sessions about the three factors which have emerged as risks: female gender, the choice of heparin, and the use of glycoprotein 2b3a inhibition.